Company intelligence / Profile preview

JenaValve

Irvine, California, United Statesjenavalve.com ↗

Ownership: Private
Employees: ~150
Development stage: Commercial

Overview

The pivotal ALIGN‑AR trial of the Trilogy Heart Valve System met primary safety and efficacy endpoints at both the one-year and two-year marks. Significant residual regurgitation was eliminated in all patients, with strong safety outcomes including low all-cause mortality at one year. The device has CE mark approval in Europe for both AR and AS, with U.S. FDA approval anticipated by late 2025.

Therapeutic areas: Cardiovascular
Modalities: DeviceBiologic
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Trilogy Heart Valve System

Commercial

Indications: Aortic regurgitation, Aortic stenosis

Partnerships

Peijia Medical Limited – exclusive licensing/commercialization partnership for Greater China region

Beyond the preview

Go deeper on JenaValve.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JenaValve.

Explore the full profile